Patents by Inventor Matthew M. Seavey

Matthew M. Seavey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TNFRSF25-MEDIATED TREATMENTS OF IMMUNE DISEASES AND DISORDERS
    Publication number: 20220340672
    Abstract: The present disclosure is directed to a method of treating or preventing diabetes, prediabetes, and/or glucose intolerance using TNF Receptor Superfamily Member 25 (TNFRSF25) agonistic antibody or antigen binding fragment thereof. The disclosure is also directed to methods for increasing graft survival and for treating or preventing graft-versus-host disease (GVHD) using TNFRSF25 agonistic antibody.
    Type: Application
    Filed: September 28, 2020
    Publication date: October 27, 2022
    Inventors: Matthew M. SEAVEY, Jeff T. HUTCHINS, Rahul R. JASUJA, A.M. James SHAPIRO, Braulio A. MARFIL-GARZA
  • METHODS OF TREATING CANCER USING TNFRSF25 ANTIBODIES
    Publication number: 20220298252
    Abstract: The present disclosure is directed to a method of treating cancer using a TNFRSF25 agonistic antibody or antigen binding fragment thereof and their combinations with additional therapies such as cancer vaccines and/or checkpoint inhibitors.
    Type: Application
    Filed: August 27, 2020
    Publication date: September 22, 2022
    Inventors: Matthew M. SEAVEY, Jeff T. HUTCHINS, Rahul R. JASUJA
  • TREATMENT OF MULTIPLE SCLEROSIS WITH A 1,2,4-TRIAZOLO [1,5A] PYRIDINE DERIVATIVE
    Publication number: 20160303116
    Abstract: The present disclosure provides methods and compositions for treating chronic autoimmune diseases, such as multiple sclerosis, using [8-(4-methanesulfonyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-[3-(4-methyl-piperazin-1-yl)-phenyl]-amine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 10, 2014
    Publication date: October 20, 2016
    Inventors: Pawel T. DOBRZANSKI, Joel KAYE, Arie ORBACH, Bruce A. RUGGERI, Matthew M. SEAVEY
  • Proteasome inhibitor delanzomib for use in the treatment of lupus
    Patent number: 9340559
    Abstract: The present invention provides a method for treating lupus in a subject, comprising the step of administering to the subject Compound A.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: May 17, 2016
    Assignee: Cephalon, Inc.
    Inventors: Bruce A. Ruggeri, Matthew M. Seavey
  • COMPOSITIONS AND METHODS FOR PREVENTION OF ESCAPE MUTATION IN THE TREATMENT OF HER2/NEU OVER-EXPRESSING TUMORS
    Publication number: 20150366955
    Abstract: This invention provides compositions and methods for treating and vaccinating against a Her2/neu antigen-expressing tumor and inducing an immune response against dominant in a non-human animal.
    Type: Application
    Filed: February 25, 2014
    Publication date: December 24, 2015
    Inventors: VAFA SHAHABI, Anu Wallecha, Paulo C. Maciag, Yvonne Paterson, Nicola Mason, Matthew M. Seavey
  • COMPOSITIONS AND METHODS FOR PREVENTION OF ESCAPE MUTATION IN THE TREATMENT OF HER2/NEU OVER-EXPRESSING TUMORS
    Publication number: 20150238584
    Abstract: This invention provides compositions and methods for treating and vaccinating against a Her2/neu antigen-expressing tumor and inducing an immune response against dominant in a non-human animal.
    Type: Application
    Filed: February 25, 2014
    Publication date: August 27, 2015
    Inventors: VAFA SHAHABI, Anu Wallecha, Paulo C. Maciag, Yvonne Paterson, Nicola Mason, Matthew M. Seavey
  • Treatment of chronic inflammation with a 1,2,4-triazolo [1,5a] pyridine derivative
    Patent number: 9034876
    Abstract: This application describes and provides a method of treating diseases or disorders characterized by chronic systemic inflammation, such as rheumatoid arthritis, using a compound that inhibits JAK2 kinase.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: May 19, 2015
    Assignee: Cephalon, Inc.
    Inventors: Pawel T. Dobrzanski, Matthew M. Seavey
  • Janus kinase 2 (JAK2) inhibitor for the treatment of lupus
    Patent number: 9023853
    Abstract: The present invention provides a method for treating lupus in a subject, comprising the step of administering to the subject COMPOUND A.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: May 5, 2015
    Assignee: Cephalon, Inc.
    Inventors: Pawel T. Dobrzanski, Matthew M. Seavey
  • JANUS KINASE 2 (JAK2) INHIBITOR FOR THE TREATMENT OF LUPUS
    Publication number: 20140024655
    Abstract: The present invention provides a method for treating lupus in a subject, comprising the step of administering to the subject COMPOUND A
    Type: Application
    Filed: June 6, 2013
    Publication date: January 23, 2014
    Applicant: Cephalon, Inc.
    Inventors: Pawel T. Dobrzanski, Matthew M. Seavey
  • PROTEASOME INHIBITOR DELANZOMIB FOR USE IN THE TREATMENT OF LUPUS
    Publication number: 20130345174
    Abstract: The present invention provides a method for treating lupus in a subject, comprising the step of administering to the subject Compound A.
    Type: Application
    Filed: March 2, 2012
    Publication date: December 26, 2013
    Applicant: Cephalon, Inc.
    Inventors: Bruce A. Ruggeri, Matthew M. Seavey
  • Treatment of Chronic Inflammation with a 1,2,4-Triazolo [1,5a] Pyridine Derivative
    Publication number: 20130267535
    Abstract: This application describes and provides a method of treating diseases or disorders characterized by chronic systemic inflammation, such as rheumatoid arthritis, using a compound that inhibits JAK2 kinase.
    Type: Application
    Filed: June 6, 2013
    Publication date: October 10, 2013
    Inventors: Pawel T. Dobrzanski, Matthew M. Seavey